CurrentBluecross IdahoPolicy MP 7.01.663

Treatment of Nasal Valve Collapse and Nasal Septal Swell Bodies

Customize your policy alerts

Sign up for Bluecross Idaho Policy MP 7.01.663 alerts

Get alerted when Policy MP 7.01.663 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Medical policy governing coverage of surgical and implant-based treatments for nasal valve collapse and procedures for nasal septal swell bodies for Blue Cross of Idaho members.

Policy Summary

PayerBluecross Idaho

PolicyTreatment of Nasal Valve Collapse and Nasal Septal Swell Bodies

Policy CodePolicy MP 7.01.663

Change TypeNo material changes

Effective DateAug 1, 2026

Last ReviewApr 30, 2026

Next Review DateApr 30, 2026

Key ActionSubmit prior authorization with documentation of chronic nasal obstruction, positive Cottle or lateralization test, and exclusion of other structural causes.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3Clinical criteria required for graft procedures

3Investigational determinations

137Patients randomized in RCT

24 moDevice durability eval

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentBluecross IdahoPolicy MP 7.01.663

Treatment of Nasal Valve Collapse and Nasal Septal Swell Bodies

Customize your policy alerts

Sign up for Bluecross Idaho Policy MP 7.01.663 alerts

Get alerted when Policy MP 7.01.663 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Medical policy governing coverage of surgical and implant-based treatments for nasal valve collapse and procedures for nasal septal swell bodies for Blue Cross of Idaho members.

Policy Summary

PayerBluecross Idaho

PolicyTreatment of Nasal Valve Collapse and Nasal Septal Swell Bodies

Policy CodePolicy MP 7.01.663

Change TypeNo material changes

Effective DateAug 1, 2026

Last ReviewApr 30, 2026

Next Review DateApr 30, 2026

Key ActionSubmit prior authorization with documentation of chronic nasal obstruction, positive Cottle or lateralization test, and exclusion of other structural causes.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3Clinical criteria required for graft procedures

3Investigational determinations

137Patients randomized in RCT

24 moDevice durability eval

Implant integrity reported

Coverage Determinations and Criteria

Cartilage graft procedures (medically necessary)

Covered when ALL of the following are met

Primary coverage criteria: 1. Chronic nasal obstruction (e.g., nasal congestion, facial pain/pressure, mouth breathing, headache, or sleep disturbance) due to vestibular stenosis or alar collapse; AND 2. Demonstration of improvement of nasal airflow by either: a) Positive Cottle maneuver OR b) Lateralization of the upper lateral cartilage from inside the nose with an object (e.g., swab or nasal speculum); AND 3. Documentation that other causes have been ruled out as the primary cause of nasal obstruction (e.g., sinusitis, allergic rhinitis, vasomotor rhinitis, nasal polyposis, adenoid hypertrophy, nasopharyngeal masses, nasal septal deviation, turbinate hypertrophy, or choanal atresia).

Color photos clearly documenting internal and/or external valve collapse may be requested.

Evidence-based criteria elements

Evidence-based considerations for using an absorbable lateral nasal implant

Population and diagnosis: Adult patients with severe symptomatic nasal obstruction due to internal nasal valve collapse (NVC) confirmed by clinical history and examination (including Cottle or modified Cottle maneuvers) and exclusion of other structural or mucosal causes via anterior rhinoscopy or nasal endoscopy.severe to extreme NOSE score per NOSE scale

NOSE used to stratify severity

Intervention specifics: Unilateral or bilateral insertion of an absorbable PLLA-co-DL implant (1 mm diameter x 24 mm length with forked distal end) into the lateral nasal wall using the provided 16-gauge insertion device; implant is absorbed over ~18 months and is described to maintain integrity for ~12 months with remodeling/collagen replacement through 24 months.implant dimensions and composition as specified

Device described as LATERA in product information

Outcomes and follow-up: Measure symptom change using the NOSE score with early assessment at ~1 month and durability assessment through at least 24 months; monitor for adverse events including mild pain, foreign body sensation, swelling, inflammation, infection, and device retrieval/removal.NOSE improvement and adverse event surveillance

NOSE is validated and follow-up at 1 month and ≥24 months recommended

Evidence-summary criteria

Clinical evidence summary and limitations informing coverage:

RCT evidence: One sham-controlled randomized trial (Stolovitzky et al. 2019; N=137) demonstrated statistically significant short-term (3-month) improvements in NOSE responder rate and scores for the implant versus sham; however, limitations included non–intent-to-treat analysis, implant removals excluded from analysis, and lack of long-term controlled data.

See RCT summary and Tables referenced in document.

Nonrandomized evidence: Multiple prospective single-arm cohort studies (total n≈307) and postmarketing cohorts reported substantial mean NOSE score improvements and high responder rates at 24 months, but these studies had high loss to follow-up, no comparators, and variable concomitant procedures.

Loss to follow-up and sensitivity analyses are summarized in cohort reports.

Safety and device issues: Reported device-related adverse events included pain, foreign body sensation, localized swelling, inflammation, infection, and device retrievals/removals; retrievals/extrusions occurred in larger cohorts in about 4–8% of patients and often early in follow-up.

Adverse events and retrieval rates reported in trials and cohorts.

Absorbable lateral nasal valve implant — stance

Coverage stance derived from evidence summaries in this section:

Absorbable lateral nasal valve implant: Evidence is insufficient to determine that the absorbable lateral nasal valve implant improves net health outcome; short-term randomized data show benefit at 3 months but long-term uncontrolled data have high attrition and device retrievals (~4%); no comparative studies versus septoplasty or turbinate reduction were identified.

RCT showed short-term benefit but longer-term controlled data are lacking.

Nasal valve suspension — stance

Nasal valve suspension: Evidence is insufficient to determine that nasal valve suspension improves net health outcome; well-designed controlled studies with long-term results are needed.

Existing small case series report variable benefit and some complications.

Radiofrequency ablation — stance

Radiofrequency ablation of nasal tissues: Evidence is insufficient to determine that radiofrequency ablation of nasal tissues improves net health outcome for symptomatic internal nasal valve collapse; controlled long-term studies and independent research are needed.

Available data are limited to small case series reporting symptomatic improvement.

Nasal septal swell bodies — stance

Nasal septal swell bodies reduction: Evidence is insufficient to determine that reduction (surgical or radiofrequency) of nasal septal swell bodies improves net health outcome; existing reports are limited case series and narrative reviews with unclear long-term results and physiologic role of NSB not fully understood.

Further well-designed controlled studies with long-term follow-up are needed.

The policy designates certain implant- and procedure-based approaches to nasal valve compromise and septal swell bodies as investigational. Specifically, insertion of an absorbable lateral nasal implant (e.g., Latera®) and nasal valve suspension are identified as investigational procedures. In addition, ablation, coblation, shaving, or other methods of reduction of nasal septal swell bodies for treatment of sinonasal disease or nasal obstruction are considered investigational. These investigational determinations indicate that available evidence is insufficient to support routine coverage for these interventions under this policy.

Diagnosis of internal nasal valve collapse (NVC) is primarily clinical. The policy emphasizes history and physical examination maneuvers — including the Cottle or modified Cottle maneuver — plus anterior rhinoscopy or nasal endoscopy to exclude other anatomic or mucosal causes (for example, septal deviation or turbinate hypertrophy). It also states that radiographic studies are not generally indicated for the diagnosis of NVC and should not be relied on routinely when assessing candidacy for intervention.

Although the document summarizes relevant studies, it does not list explicit study-level exclusion criteria in the policy text. The review notes that several nonrandomized studies were excluded from evidence synthesis because of retrospective design, short follow-up (e.g., 3 months), heterogenous indications, or variable surgical techniques. These methodological limitations were important in assessing applicability of the published data to candidate selection and expected outcomes.

The policy does not provide a discrete list of coverage exclusions tied to specific patient characteristics; instead, it frames several interventions as having insufficient evidence to determine net health benefit. As a result, insertion of absorbable lateral nasal implants, nasal valve suspension, radiofrequency ablation for NVC, and reduction of nasal septal swell bodies are labeled in the policy rationale as lacking sufficient evidence and therefore treated as investigational or unsupported for routine coverage pending more rigorous data.

Policy history shows iterative updates to literature review and investigational determinations. Investigational policy statements for nasal valve suspension, radiofrequency ablation, and reduction/ablation of nasal swell bodies were added in the 2024–2025 update cycle, and later administrative revisions moved or clarified some procedure-level designations; the document records multiple replacement and review dates with the most recent adoption effective 08/01/2026. These entries document the evolution of investigational language and cross-references to other policies (e.g., MP 7.01.156 for radiofrequency procedures).

The policy explicitly names insertion of an absorbable lateral nasal implant (e.g., Latera®) as investigational. It also indicates that nasal valve suspension techniques are investigational. The regulatory status of the Latera device (FDA 510(k) clearance) is discussed elsewhere in the document, but the policy stance remains that device insertion for NVC is investigational based on the current evidence synthesis.

The policy excerpts provided do not state any procedure or indication as unequivocally not medically necessary in standalone language; rather, they emphasize that evidence is insufficient to determine net health benefit for several interventions. One specific statement elsewhere in the document, however, treats ablation of nasal septal swell bodies for sinonasal disease or nasal obstruction as investigational and not covered (see related policy sections).

Within the cited evidence summaries and tables, the document does not use an explicit phraseology across the excerpts that consistently labels individual interventions as not medically necessary, but it does highlight limitations (high attrition, lack of comparators, incomplete analyses) that could support NMN determinations in the absence of adequate documentation or higher‑quality comparative evidence.

Overall, the policy concludes that the evidence base is inadequate to determine improvement in net health outcomes for several interventions targeting nasal valve compromise and septal swell bodies. For the absorbable lateral nasal implant, short-term randomized data show benefit at 3 months but longer-term and comparative evidence are limited and attrition is high; for nasal valve suspension and radiofrequency or septal swell body reduction, the policy states that well‑designed controlled studies with long-term follow-up are needed. Consequently, the document characterizes these interventions as having insufficient evidence to support routine coverage.

Coding and Regulatory Identifiers

Coding table referencedmixed

No codes listed

Regulatory identifiersmixed

K161191	510(k) number for LATERA absorbable nasal implant
NHB	FDA product code listed for LATERA in Table 1 (product code)

Coding references in documentmixed

affected codes

Document does not list explicit CPT/HCPCS codes in this section; references to coding are generic.

Procedure CPT examplesCPT

30117	Excision or destruction (e.g., laser), intranasal lesion; internal approach.
30465	Repair of nasal vestibular stenosis (e.g., spreader grafting, lateral nasal wall reconstruction) Repair of nasal valve collapse with subcutaneous/ submucosal lateral wall.
30468	Repair of nasal vestibular stenosis (e.g., spreader grafting, lateral nasal wall reconstruction) Repair of nasal valve collapse with subcutaneous/ submucosal lateral wall.

ICD-10-PCS exampleICD-10

J34.9

Unspecified disorder of nose and nasal sinuses (listed under ICD-10-PCS in document)

HCPCS exampleHCPCS

HCPCS: N/A

implant(s) (e.g., Latera®) — HCPCS listing noted as N/A in table

Follow-up and implant integrity timeline

Implant integrity periodManufacturer/clinical reports: implant integrity maintained for approximately 12 months after implantation while a fibrous capsule forms

Remodeling/durability assessmentCollagen remodeling replacing the implant persists through 24 months; durability should be assessed to at least 24 months

Follow-up schedule (recommended)Early outcome assessment at ~1 month and longer-term assessments through ≥24 months to evaluate symptom durability and device remodeling

Responder definition

Responder threshold (trial definition)Defined as ≥20% decrease or a decrease in 1 category on the NOSE score

Prior Authorization, Documentation, and Billing Guidance

Prior Authorization

Prior authorization requirement

Prior authorization: submit documentation showing that criteria for medically necessary cartilage graft procedures are met, including chronic nasal obstruction due to vestibular stenosis or alar collapse, demonstration of improved airflow by a positive Cottle maneuver or lateralization of the upper lateral cartilage, and documentation that other causes of nasal obstruction have been ruled out. Color photos documenting internal/external valve collapse may be requested.

Chronic nasal obstruction due to vestibular stenosis or alar collapse
Positive Cottle maneuver or lateralization test demonstrating improved airflow
Documentation excluding other primary causes of obstruction (e.g., sinusitis, allergic rhinitis, septal deviation, turbinate hypertrophy)

Prior Authorization

Prior authorization: device and clinical baseline

When requesting authorization for an absorbable lateral nasal wall implant, include device specifics and baseline clinical data: description of the implant (PLLA-co-DL, 1 mm × 24 mm, forked distal end), expected implant integrity (~12 months) with remodeling through 24 months, and baseline NOSE severity.

Clinical Background

Nasal obstruction is the subjective sensation of reduced nasal airflow and may be unilateral or bilateral. Structural causes include trauma or prior rhinologic surgery, and mucosal conditions (for example, allergic rhinitis or turbinate hypertrophy) can also contribute. The internal nasal valve is the narrowest portion of the nasal airway and small changes in its angle or lateral cartilage support substantially affect resistance to airflow. Clinical assessment includes history, inspection, and functional maneuvers such as the Cottle or modified Cottle maneuver and anterior rhinoscopy or endoscopy to identify dynamic lateral wall collapse and to exclude other anatomic causes of obstruction.

Key Terms and Definitions

Internal nasal valve

Anatomic locationNarrowest part of the nasal airway bordered by soft tissue between the upper and lower lateral cartilages, anterior inferior turbinate, and septum

Normal angleAngle at junction between septum and upper lateral cartilage normally ~10°–15°

Physiologic importanceAccounts for at least half of nasal airway resistance; minor narrowing can cause symptomatic obstruction

Cottle maneuver / modified Cottle maneuver

Cottle maneuverManual lateral pull of the cheek; subjective symptom improvement with inspiration suggests nasal valve widening and contribution to obstruction

Modified Cottle maneuverClinician inserts a cotton swab or curette intranasally to support lateral cartilage; patient-reported improvement suggests valve contribution

Document Revision History

2026-04-30Annual review / policy replaceLatest

Blue Cross of Idaho adopted changes effective 2026-08-01 with added language clarifying types of reduction to nasal swell bodies; annual review with no changes to policy statements noted in prior entry.

2026-02-26Policy replace

Policy replaced (2/26/26) with updates noted in supporting text (entry begins in chunk 78); administrative update preceding April 30, 2026 adoption.

2025-06-01

Policy Summary

PayerBluecross Idaho

PolicyTreatment of Nasal Valve Collapse and Nasal Septal Swell Bodies

Policy CodePolicy MP 7.01.663

Change TypeNo material changes

Effective DateAug 1, 2026

Last ReviewApr 30, 2026

Next Review DateApr 30, 2026

Key ActionSubmit prior authorization with documentation of chronic nasal obstruction, positive Cottle or lateralization test, and exclusion of other structural causes.

SourceLink

On This Page

Study limitations affecting coverage: Limitations that affect interpretation include lack of long-term control arm, high attrition, non–intent-to-treat analyses, heterogenous patient selection and concomitant procedures, and limited objective measures of nasal valve collapse.

These limitations are detailed in evidence tables and text.

Outcome instrumentNOSE (Nasal Obstruction Symptom Evaluation) used to determine responder status in trials

Timing for responder assessmentResponder status reported at early (3 months randomized data) and longer-term (24 months uncontrolled) follow-up

Device composition and dimensions: poly(L-lactide-co-D-L-lactide) 70:30, 1 mm diameter, 24 mm length, forked distal end
Packaging/delivery: 16-gauge insertion device
Expected implant integrity ~12 months; remodeling/collagen replacement through 24 months
Baseline NOSE score (severity classification)

Prior Authorization

Prior authorization requirement (severity documentation for implant coding)

If coding for insertion of an absorbable lateral wall nasal implant, prior authorization should document severe-to-extreme NOSE score and prior conservative management or rationale for selecting the implant versus alternative surgery.

Severe to extreme NOSE score documented (per NOSE severity ranges)
Evidence of prior conservative measures or clinical rationale for implant selection

Prior Authorization

Prior authorization: follow plan procedures

The policy does not list explicit PA codes; follow Bluecross Idaho plan-specific prior authorization procedures for interventions lacking sufficient evidence and submit requested clinical documentation per plan rules.

Follow member-specific prior authorization processes
Provide additional documentation when plan requests further clinical detail

Billing Rule

Coding reference and potential prior authorization

Codes are provided for reference only (e.g., CPT 30117, 30465, 30468); inclusion does not guarantee coverage—prior authorization may be required per member plan and policy rules.

CPT examples listed: 30117, 30465, 30468
HCPCS listed as N/A for implants (e.g., Latera); inclusion is informational only

Step Therapy

Conservative therapy considered

Document trials of conservative, non-surgical treatments when clinically appropriate: externally applied adhesive strips, nasal dilators/cones, or other devices that support the lateral nasal wall.

External adhesive nasal strips (apply Cottle principle)
Internal nasal dilators or cones (modified Cottle principle)

Step Therapy

Conservative therapy alternatives

List non-surgical alternatives and medical management in the chart as comparators prior to implant insertion when applicable.

External adhesive strips or intranasal cones
Medical management and consideration of surgical grafting alternatives

Step Therapy

Step therapy note

Document consideration of prior medical management or alternative surgical procedures; the policy notes no formal step-therapy algorithm is specified.

Record prior conservative treatments or rationale for proceeding to implant/surgery
No mandated sequence of trials required by this policy

Note

No formal step therapy specified

There is no formal required step-therapy sequence specified in this policy; surgical treatment is identified as the primary mode for nasal valve compromise, with non-surgical adjuncts usable for some patients.

Surgical repair is primary for nasal valve compromise per AAO-HNS consensus
Nasal strips, stents, or cones may be used for some patients

Prior Authorization

Provider actions

Ensure submitted authorization requests contain all clinical evidence listed in the policy (history, exam, maneuvers, baseline NOSE, imaging not generally indicated) and any plan-requested materials.

Provide requested supporting documentation promptly to avoid processing delays
Include plan-specific forms or prior authorization identifiers if required

Documentation Required

Required clinical documentation

Required documentation: submit clinical documentation demonstrating chronic nasal obstruction due to vestibular stenosis or alar collapse, evidence of improved airflow with a positive Cottle maneuver or lateralization test, and documentation that other causes have been excluded; color photos may be requested.

Chronic symptom history consistent with vestibular stenosis or alar collapse
Positive Cottle maneuver or lateralization documented
Exclusion of other causes (e.g., sinusitis, allergic rhinitis, septal deviation)

Documentation Required

Required clinical documentation (exam and maneuvers)

Include a focused physical exam and specific maneuvers in documentation: clinical history, Cottle or modified Cottle maneuver, anterior rhinoscopy or endoscopy to exclude other structural or mucosal causes, baseline NOSE score, and symptom duration.

Document performance and result of Cottle or modified Cottle maneuver
Include anterior rhinoscopy or nasal endoscopy findings to rule out septal deviation or turbinate hypertrophy
Record baseline NOSE score and symptom duration

Documentation Required